Skip to main content
OpenTrials
Completed

NCT Number: NCT05678764

Evaluation of a Conversational Information Collection Tool to Access Talk Therapy

This is an observational study evaluating a conversational information collection tool to access talk therapy.

The patient outcome data will be compared between people who refer to talk therapy via the conversational information collection tool and people who refer using other means.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mental Health Issue

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, Surrey, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant meets minimum age requirements for the talk therapy service Participant's registered GP is within the talk therapy service's CCG catchment area

Exclusion criteria

  • Participants who are in crisis (defined by requiring urgent care or being at an urgent risk of harm)

Treatment and study plan

Conversational Information Collection Tool

Device

Conversational Information Collection Tool that facilitates the self-referral to talk therapy.

Primary outcomes

  1. Change from baseline depression score to after treatment

    Time frame: The definition of reliable and clinically significant improvement is based on a comparison of pre-treatment (at time of referral, on the day of consenting) and post-treatment (assessed at point of discharge, an average of 5 months) clinical score.

    The primary outcome will be defined as reliable and clinically significant improvement in clinical scores after treatment. Hereby, the investigators will test for changes in depression scores using Patient Health Questionnaire-9 (PHQ-9: posttreatment scores <10 and improved by ≥6 points). PHQ-9 includes 9 questions scored between 0 and 3, with higher scores indicating more severe depression.

  2. Change from baseline anxiety score to after treatment

    Time frame: The definition of reliable and clinically significant improvement is based on a comparison of pre-treatment (at time of referral, on the day of consenting) and post-treatment (assessed at point of discharge, an average of 5 months) clinical score

    The primary outcome will be defined as reliable and clinically significant improvement in clinical scores after treatment. Hereby, we will test for changes in anxiety scores using Generalised Anxiety Disorder Assessment (GAD-7: posttreatment scores <8 and improved by ≥4 points).GAD-7 includes 7 questions scored between 0 and 3, with higher scores indicating more severe anxiety.

  3. Clinical assessment times

    Time frame: This measure will be available after the clinical assessment (up to average of 1 month from consenting).

    Improved clinical efficiency will be indicated by reduced assessment times, measured by the average time per clinical assessment (in minutes).

Secondary outcomes

  1. Waiting times

    Time frame: This measure will be available after the clinical assessment (up to average of 1 month from consenting).

    Patient waiting times for treatment will be measured as the time between the date of (self-referral) and the date of the clinical assessment.

  2. Referral Dropout Rates

    Time frame: During Information Collection Tool interaction (day 1)

    Patient referral dropout will be measured as any individual who consented to participate in the study, but did not complete all requested clinical information during the referral process.

  3. Assessment Dropout Rates

    Time frame: At time point of treatment termination using standard IAPT definitions (assessed up to 3 months)

    Clinical assessment dropout will be measured as any cancellation or "Did Not Attend" event for patients who successfully had a clinical assessment slot (eg. time and date) organised. The treatment cohort (Limbic Access with AI pathway) will be evaluated against a cohort of patients going through limbic Access' standard pathway across the same services and over the same time window as the study will be used for comparison.

  4. Treatment Dropout Rates

    Time frame: At time point of treatment termination using standard IAPT definitions (assessed up to 3 months)

    Treatment dropout will be measured using a "dropout" label which is added to a patient's file in the service's patient management system by the treating clinician when a dropout event occurs. The treatment cohort (Limbic Access +AI pathway) will be evaluated against a cohort of patients going through limbic Access' standard pathway across the same services and over the same time window as the study will be used for comparison.

Sponsors and collaborators

Lead sponsor

Limbic Limited

Industry

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jan 10, 2023
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.